Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rose, P. G.
Right arrow Articles by Homesley, H. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rose, P. G.
Right arrow Articles by Homesley, H. D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 16, 405-410, Copyright © 1998 by American Society of Clinical Oncology


ARTICLES

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

PG Rose, JA Blessing, AR Mayer and HD Homesley
Department of Obstetrics and Gynecology, University Hospitals of Cleveland, Case Western Reserve University, OH, USA.

PURPOSE: A phase II trial was conducted to determine the activity of prolonged oral etoposide in platinum-resistant and platinum-sensitive ovarian carcinoma. PATIENTS AND METHODS: Platinum-resistant disease was defined as progression on platinum-based chemotherapy or recurrence within 6 months of completing therapy. The starting dose was 50 mg/m2/d (30 mg/m2/d for prior radiotherapy) for 21 days, every 28 days. A dose escalation to a maximum dose of 60 mg/m2/d was prescribed. RESULTS: Of 99 patients entered, 97 were assessable for toxicity and 82 were assessable for response. Among 41 platinum-resistant patients a 26.8% response rate (7.3% complete response [CR] and 19.5% partial response [PR] rate) occurred. The median response duration was 4.3 months (range, 1.3 to 8.7), median progression-free interval (PFI) was 5.7 months (range, 0.8 to 30.8+), and median survival time was 10.8 months (range, 1.9 to 45.8). Twenty-five of 41 platinum-resistant patients had also previously received paclitaxel; of which eight (32%) responded. Among 41 platinum-sensitive patients, a 34.1% response rate (14.6% CR and 19.5% PR rate) occurred. The median response duration was 7.5 months (range, 1.9 to 15.2+), median PFI was 6.3+ months (range, 0.9 to 20.4), and median survival time was 16.5+ months (range, 0.9 to 34.8). Of 97 patients assessable for toxicity, grade 3 or 4 hematologic toxicity was common, with leukopenia occurring in 41.2% (grade 3, 29%; grade 4, 12%), neutropenia in 45.4% (grade 3, 20%; grade 4, 25%), thrombocytopenia in 9% (grade 3, 5%; grade 4, 4%), and anemia in 13.4%. Three treatment-related deaths occurred: two from neutropenic sepsis and one from thrombocytopenic bleeding after an overdose. One patient developed leukemia. CONCLUSION: This regimen is active in platinum- resistant and platinum-sensitive ovarian carcinoma. Additionally, the regimen is active in paclitaxel-resistant ovarian carcinoma.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Ann OncolHome page
J. M. Del Campo, A. Roszak, M. Bidzinski, T. E. Ciuleanu, T. Hogberg, M. Z. Wojtukiewicz, A. Poveda, K. Boman, A. M. Westermann, C. Lebedinsky, et al.
Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer
Ann. Onc., November 1, 2009; 20(11): 1794 - 1802.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. S. Miller, J. A. Blessing, C. N. Krasner, R. S. Mannel, P. Hanjani, M. L. Pearl, S. E. Waggoner, and C. H. Boardman
Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group
J. Clin. Oncol., June 1, 2009; 27(16): 2686 - 2691.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
G. D. Aletti, M. M. Gallenberg, W. A. Cliby, A. Jatoi, and L. C. Hartmann
Current Management Strategies for Ovarian Cancer
Mayo Clin. Proc., June 1, 2007; 82(6): 751 - 770.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
M. Markman
New, Expanded, and Modified Use of Approved Antineoplastic Agents in Ovarian Cancer
Oncologist, February 1, 2007; 12(2): 186 - 190.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
T. Ohta, M. Ohmichi, T. Hayasaka, S. Mabuchi, M. Saitoh, J. Kawagoe, K. Takahashi, H. Igarashi, B. Du, M. Doshida, et al.
Inhibition of Phosphatidylinositol 3-Kinase Increases Efficacy of Cisplatin in in Vivo Ovarian Cancer Models
Endocrinology, April 1, 2006; 147(4): 1761 - 1769.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Campos, O. Hamid, M. V. Seiden, A. Oza, M. Plante, R. K. Potkul, P. F. Lenehan, E. P. Kaldjian, M. L. Varterasian, C. Jordan, et al.
Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer
J. Clin. Oncol., August 20, 2005; 23(24): 5597 - 5604.
[Abstract] [Full Text] [PDF]


Home page
J Oncol Pharm PractHome page
H. S Sano, J A. Waddell, D. A Solimando Jr, P. Doulaveris, and R. Myhand
Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost
Journal of Oncology Pharmacy Practice, March 1, 2005; 11(1): 21 - 30.
[Abstract] [PDF]


Home page
The OncologistHome page
P. G. Rose
Pegylated Liposomal Doxorubicin: Optimizing the Dosing Schedule in Ovarian Cancer
Oncologist, March 1, 2005; 10(3): 205 - 214.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. J. Herzog
Recurrent Ovarian Cancer: How Important Is It to Treat to Disease Progression?
Clin. Cancer Res., November 15, 2004; 10(22): 7439 - 7449.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
G. Aravantinos, D. Bafaloukos, G. Fountzilas, C. Christodoulou, C. Papadimitriou, N. Pavlidis, H. P. Kalofonos, H. Gogas, P. Kosmidis, and M. A. Dimopoulos
Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer
Ann. Onc., July 1, 2003; 14(7): 1094 - 1099.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. A. Bookman
Developmental Chemotherapy and Management of Recurrent Ovarian Cancer
J. Clin. Oncol., May 15, 2003; 21(90100): 149s - 167.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M.-C. Le Deley, T. Leblanc, A. Shamsaldin, M.-A. Raquin, B. Lacour, D. Sommelet, A. Chompret, J.-M. Cayuela, C. Bayle, A. Bernheim, et al.
Risk of Secondary Leukemia After a Solid Tumor in Childhood According to the Dose of Epipodophyllotoxins and Anthracyclines: A Case-Control Study by the Societe Francaise d'Oncologie Pediatrique
J. Clin. Oncol., March 15, 2003; 21(6): 1074 - 1081.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
T. J. Herzog
Update on the Role of Topotecan in the Treatment of Recurrent Ovarian Cancer
Oncologist, October 1, 2002; 7(90005): 3 - 10.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
C. J. Dunton
Management of Treatment-Related Toxicity in Advanced Ovarian Cancer
Oncologist, October 1, 2002; 7(90005): 11 - 19.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
D. K. Armstrong
Relapsed Ovarian Cancer: Challenges and Management Strategies for a Chronic Disease
Oncologist, October 1, 2002; 7(90005): 20 - 28.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
R. F. Ozols
Recurrent Ovarian Cancer: Evidence-Based Treatment
J. Clin. Oncol., March 1, 2002; 20(5): 1161 - 1163.
[Full Text] [PDF]


Home page
JCOHome page
D. S. Dizon, M. L. Hensley, E. A. Poynor, P. Sabbatini, C. Aghajanian, A. Hummer, E. Venkatraman, and D. R. Spriggs
Retrospective Analysis of Carboplatin and Paclitaxel as Initial Second-Line Therapy for Recurrent Epithelial Ovarian Carcinoma: Application Toward a Dynamic Disease State Model of Ovarian Cancer
J. Clin. Oncol., March 1, 2002; 20(5): 1238 - 1247.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. N. Gordon, J. T. Fleagle, D. Guthrie, D. E. Parkin, M. E. Gore, and A. J. Lacave
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
J. Clin. Oncol., July 15, 2001; 19(14): 3312 - 3322.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. N. Gordon, C. O. Granai, P. G. Rose, J. Hainsworth, A. Lopez, C. Weissman, R. Rosales, and T. Sharpington
Phase II Study of Liposomal Doxorubicin in Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer
J. Clin. Oncol., September 17, 2000; 18(17): 3093 - 3100.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. G. Rose, M. Rodriguez, S. Waggoner, B. E. Greer, I. R. Horowitz, J. M. Fowler, and W. P. McGuire
Phase I Study of Paclitaxel, Carboplatin, and Increasing Days of Prolonged Oral Etoposide in Ovarian, Peritoneal, and Tubal Carcinoma: A Gynecologic Oncology Group Study
J. Clin. Oncol., August 16, 2000; 18(16): 2957 - 2962.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
M. Seiden
Highlights in Ovarian Cancer
Oncologist, August 1, 2000; 5(4): 267 - 273.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
G. Toffoli, R. Sorio, P. Aita, D. Crivellari, G. Corona, A. Bearz, I. Robieux, A. M. Colussi, F. Stocco, and M. Boiocchi
Dose-finding and Pharmacologic Study of Chronic Oral Idarubicin Therapy in Metastatic Breast Cancer Patients
Clin. Cancer Res., June 1, 2000; 6(6): 2279 - 2287.
[Abstract] [Full Text]


Home page
JCOHome page
M. J. Piccart, J. A. Green, A. J. Lacave, N. Reed, I. Vergote, P. Benedetti-Panici, A. Bonetti, V. Kristeller-Tome, C. M. Fernandez, D. Curran, et al.
Oxaliplatin or Paclitaxel in Patients With Platinum-Pretreated Advanced Ovarian Cancer: A Randomized Phase II Study of the European Organization for Research and Treatment of Cancer Gynecology Group
J. Clin. Oncol., March 13, 2000; 18(6): 1193 - 1202.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
M. Markman and M. A. Bookman
Second-Line Treatment of Ovarian Cancer
Oncologist, February 1, 2000; 5(1): 26 - 35.
[Abstract] [Full Text]


Home page
JNCI J Natl Cancer InstHome page
J. E. Groopman and L. M. Itri
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
J Natl Cancer Inst, October 6, 1999; 91(19): 1616 - 1634.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
M. A. Bookman
Extending the Platinum-Free Interval in Recurrent Ovarian Cancer: The Role of Topotecan in Second-Line Chemotherapy
Oncologist, April 1, 1999; 4(2): 87 - 94.
[Abstract] [Full Text]


Home page
JCOHome page
S. A. Cannistra
Back to the Future: Multiagent Chemotherapy in Ovarian Cancer Revisited
J. Clin. Oncol., March 1, 1999; 17(3): 741 - 741.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 1998 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online